Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC.26 Late-breaker Discussion: The PRO-TAVI Trial
Author(s): Michiel Voskuil , Harriette Van Spall Added: 1 month ago
ACC.26 – Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined onsite by Michiel Voskuil (UMC Utrecht, Utrecht, NL) to discuss the PRO‑TAVI trial, a multicenter randomized study comparing TAVI with or without routine preprocedural PCI in patients with severe aortic stenosis and concomitant coronary artery disease. PRO‑TAVI tackles the ongoing controversy over… View more

Intervention
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 8 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
EHRA 25: The European Affera Ventricular Arrhythmia Ablation Registry
Author(s): Frédéric Sacher Added: 1 year ago
EHRA 2025 - Positive safety results of the Affera mapping and ablation system for the treatment of ventricular arrhythmias (VA) show a 6% rate of major complication.Dr Frédéric Sacher (IHU Liryc, Bordeaux, FR) joins us on-site at EHRA Congress 2025 to discuss safety results from the European Affera Ventricular Arrhythmia Ablation Registry, investigating VA ablation with the Affera Sphere-9… View more

Electrophysiology & Arrhythmia
30th Annual Meeting of the ISCP
Author(s): Maki Komiyama Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
Electrophysiological Risk in the Context of Cardiac Inflammation
Author(s): Antonio Curcio , Letizia Rosa Romano , Claudia Rocca , et al Added: 3 weeks ago

Imaging & Diagnostics

Electrophysiology & Arrhythmia
Semaglutide May Aid Vascular Repair in High-Risk Patients
Added: 2 months ago Source:  Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹… View more

Cardiovascular Kidney Metabolic
30th Annual Meeting of the ISCP
Author(s): Inés Martínez-Salgado , Daniel Suárez , Manuel Sánchez , et al Added: 1 month ago

Prevention & Chronic Conditions

Electrophysiology & Arrhythmia
Research Area(s) / Expertise:
30th Annual Meeting of the ISCP
Author(s): Beatriz Nieves Ureña , Raúl Ptaszynski Lanza , Raúl Ludeña , et al Added: 1 month ago

Prevention & Chronic Conditions

Electrophysiology & Arrhythmia
Lynne Brown
Job title: Associate Director, Clinical Marketing
Lynne Brown is an Associate Director of Clinical Marketing at Philips Healthcare, with responsibility for cardiovascular ultrasound products and advanced imaging technologies. Her work focuses on clinical strategy, education, and product adoption in cardiac imaging, drawing on more than 20 years of experience in echocardiography and clinical ultrasound practice.Professional ExperienceBrown joined… View more